Porsolt and KWS team on inflammation and immunology
The co-marketing partnership is intended to provide the drug industry with a single-source contract R&D offering capable of providing a wide range of screening assays and physio-pathological models.
Paris-headquartered contract research organisation (CRO) Prosolt said that the aim is to create a suite of services to support drug discovery and development in what are important therapeutic areas with large unmet needs.
Commercial and business director Martine Lemaire explained that: “The combination of Porsolt’s expertise in functional readouts with KWS’ expertise in bioanalysis will bring a tremendous added-value to the models we are offering to our customers.”
KWS’ science director Neil Williams echoed these thoughts, suggesting the collaboration will allow “companies to access the breadth of expertise they design and carry out efficacy testing of their drugs in this important therapeutic area.”
“Both companies have a history of adding real value to drug development programmes and are focused on developing new models and assays to better predict drug efficacy in man.”
Immunology and inflammation play a significant role in most if not all diseases and, as a result, are the focus of significant amounts of drug industry R&D spending.
This demand, coupled with the continuing reduction of in-house capacity by pharmaceutical companies as well as the need to ensure that only promising candidates progress to clinical trials, may mean that the new partnership's services attract considerable attention.
